The 2nd JAK Inhibitors Drug Development Summit is now over.

Thank you to all attendees, speakers and sponsors for making the event one to remember!

If you're interested in learning more about next year's summit, please register your interest here.

Welcome to the JAK Drug Development Summit

The JAK Inhibitors Drug Development Summit brings you the only dedicated JAK inhibitor conference that will allow you to utilize the knowledge of the greatest minds and thought leaders within the realms of the JAK pathway across dermatology, rheumatology, gastroenterology, oncology and hematology.

Focusing on optimized selectivity, drug-drug interactions, safety and efficacy challenges, this summit will give you the insight to successfully translate and develop the next generation of superior JAK inhibitors.

Ensure you attend this conference to learn, to network and to strengthen your pipeline, and implement the right clinical strategy.

Meet the 2021 Expert Speaker Faculty

Gary Krishnan

Senior Research Fellow Medical

Eli Lilly & Company

Jim Lee

Group Vice President, Head of Inflammation and Autoimmunity


Luke O’Neil

Chair of Biochemistry

Trinity College Dublin

Vibeke Strand

Adjunct Professor - Clinical, Division, Immunology & Rheumatology

Stanford University School of Medicine

Barbara Klencke

Chief Medical Officer

Sierra Oncology

Brett King

Associate Professor of Dermatology

Yale University School of Medicine

Jim Cassella

Chief Development Officer

Concert Pharmaceuticals

Massimo Gadina

Director & Chief of Translational Immunology Section, Science & Technology


Hear What Past JAK Inhibitors Drug Development Summit Attendees Have To Say

The content was fantastic. The speakers were wonderful as well. It was a great educational forum and it is nice to see experts in academia, government, and industry working towards one goal of bringing safe and innovative products for patients.” 

"This forum is an opportunity to interface with industry to identify and begin to address the challenges and opportunities in the vast potential of JAK inhibitors across medicine" 


Jennifer Lee, Senior Medical Science Liaison, Sanofi Genzyme 

Brett King, Associate Professor of Dermatology, Yale School of Medicine

Who Attended In 2020?

Companies Attending